Lumos Pharma Inc. | NLNK

Lumos Pharma Inc. traded at $3.46 this Thursday February 2nd, decreasing $0.06 or 1.70 percent since the previous trading session. Looking back, over the last four weeks, Lumos Pharma Inc. lost 11.28 percent. Over the last 12 months, its price fell by 63.81 percent. Looking ahead, we forecast Lumos Pharma Inc. to be priced at 3.34 by the end of this quarter and at 3.02 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Agenus 2.65 0.06 2.32% 11.34%
Bristol-Myers Squibb 72.77 1.54 2.16% 11.97%
Capricor Therapeutics 4.20 -0.03 -0.71% 1.69%
Celldex Therapeutics 44.98 1.27 2.91% 47.86%
Aceragen Inc 4.94 0.25 5.33% -46.04%
Incyte Corp 84.49 -1.11 -1.30% 15.66%
Eli Lilly 330.70 -11.87 -3.47% 35.08%
Merck & Co 103.46 -3.52 -3.29% 31.70%
Nektar Therapeutics 3.00 0.05 1.69% -69.79%
Lumos Pharma Inc. 3.46 -0.06 -1.70% -63.81%
Pfizer 44.34 0.37 0.84% -16.94%
Prothena 55.55 1.88 3.50% 71.66%
Sarepta Therapeutics 120.25 -2.11 -1.72% 73.07%
Vascular Biogenics 0.17 0.001 0.48% -86.33%
Intrexon 1.82 0.13 7.69% -17.65%

Indexes Price Day Year
USND 12201 384.50 3.25% -12.09%
US2000 2001 40.41 2.06% 0.51%

Lumos Pharma Inc.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing and commercialization of products, and therapies for people with rare diseases. The Company's lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.